August 2012
-
The US Federal Trade Commission (FTC) is requiring Impax to divest several products in order to complete a planned merger with Amneal that the companies announced in October 2017. To satisfy the FTC requirements, Impax… Read more . . .
-
Mundipharma’s k-haler breath-activated metered dose inhaler has won two platinum A’ Design Awards in the ‘Scientific Instruments, Medical Devices and Research Equipment Design’ and ‘Ease of Use and Universal Design’ categories. In October 2017, the… Read more . . .
-
MannKind Corporation has announced that FDA is no longer requiring a Risk Evaluation and Mitigation Strategy (REMS) communication plan for Afrezza inhaled insulin. Afrezza was approved in the US in June 2014, with the FDA… Read more . . .
-
According to GlaxoSmithKline and Innoviva, the FDA has approved an expanded indication for the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol DPI, allowing the use of Trelegy Ellipta for COPD patients with airflow limitation or with acutely worsening… Read more . . .
-
A US company called Honu Xpress says that it has acquired a license for the Mystabis cannabis MDI which it claims “provides pressurized metered-doses of cannabis oil directly to the lung’s capillaries with little to… Read more . . .
-
A US biotech company called AOBiome Therapeutics said that it has initiated a Phase 2 study of an ammonia oxidizing bacteria (AOB) nasal spray for the prevention of episodic migraine. According to AOBiome, the nasal… Read more . . .
-
Swedish inhaled product developer Iconovo has announced a deal with Japanese pharmaceutical company TOA for development of Iconovo’s ICOone unit dose dry powder inhaler for the treatment of asthma and COPD. TOA’s Nishihongo facility includes… Read more . . .
-
Belgian pharmaceutical company UCB has acquired the rights to Proximagen’s USL261 midazolam nasal spray for $150 million up front and potential milestone payments of up to $220 million, the company said. An NDA for USL261… Read more . . .
-
Copley Scientific CEO Mark Copley discusses the recently published USP Chapter <1602> for testing “Spacers & Valved Holding Chambers Used with Inhalation Aerosols” Q: What does this new USP Chapter cover? A: Chapter <1602>, published… Read more . . .
-
Swedish instrument company Inhalation Sciences has announced the appointment of Lena Heffler as its new CEO effective May 7, 2018. She will succeed Fredrik Sjövall, who is expected to become Chairman of the Board. Heffler… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland